21 Einträge gefunden

1. Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines.

   1. Wagenblast, Jens
   2. Baghi, Mehran
   3. Arnoldner, Christoph
   4. Bisdas, Sotirios
   5. Gstöttner, Wolfgang
   6. Ackermann, Hanns
   7. May, Angelika

   2009 - Forschungsinformationssystem des UKE
2. Effects of combination treatment of bortezomib and dexamethasone in SCCHN cell lines depend on tumor cell specificity.

   1. Wagenblast, Jens
   2. Baghi, Mehran
   3. Arnoldner, Christoph
   4. Bisdas, Sotirios
   5. Gstöttner, Wolfgang
   6. May, Angelika
   7. Knecht, Rainald

   2008 - Forschungsinformationssystem des UKE
3. Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines.

   1. Wagenblast, Jens
   2. Hambek, Markus
   3. Baghi, Mehran
   4. Gstöttner, Wolfgang
   5. Strebhardt, Klaus
   6. Ackermann, Hanns
   7. Knecht, Rainald

   2008 - Forschungsinformationssystem des UKE
4. Effect of bortezomib on EGFR expression in head and neck squamous cell carcinoma cell lines.

   1. Wagenblast, Jens
   2. Hambek, Markus
   3. Baghi, Mehran
   4. Knecht, Rainald

   2008 - Forschungsinformationssystem des UKE
5. Effect of bortezomib and cetuximab in EGF-stimulated HNSCC.

   1. Wagenblast, Jens
   2. Baghi, Mehran
   3. Arnoldner, Christoph
   4. Bisdas, Sotirios
   5. Gstöttner, Wolfgang
   6. Ackermann, Hanns
   7. May, Angelika

   2008 - Forschungsinformationssystem des UKE
6. Inverse correlation between serum PGE2 and T classification in head and neck cancer.

   1. Hambek, Markus
   2. Baghi, Mehran
   3. Wagenblast, Jens
   4. Schmitt, Johannes
   5. Baumann, Helena
   6. Knecht, Rainald

   2007 - Forschungsinformationssystem des UKE
7. Demands on caring relatives of head and neck cancer patients.

   1. Baghi, Mehran
   2. Wagenblast, Jens
   3. Hambek, Markus
   4. Radeloff, Andreas
   5. Gstoettner, Wolfgang
   6. Scherzed, Agmal
   7. Spaenkuch, Birgit

   2007 - Forschungsinformationssystem des UKE
8. Usefulness of MRI volumetric evaluation in patients with squamous cell cancer of the head and neck treated with neoadjuvant chemotherapy.

   1. Baghi, Mehran
   2. Mack, Martin G
   3. Hambek, Markus
   4. Bisdas, Sotirios
   5. Muerthel, Ramona
   6. Wagenblast, Jens
   7. Gstoettner, Wolfgang

   2007 - Forschungsinformationssystem des UKE
9. Enhancement of docetaxel efficacy in head and neck cancer treatment by G0 cell stimulation.

   1. Hambek, Markus
   2. Werner, Christian
   3. Baghi, Mehran
   4. Gstöttner, Wolfgang
   5. Knecht, Rainald

   2007 - Forschungsinformationssystem des UKE
10. Iron oxide particle-enhanced magnetic resonance imaging for detection of benign lymph nodes in the head and neck: how reliable are the results?

    1. Baghi, Mehran
    2. Mack, Martin G
    3. Wagenblast, Jens
    4. Hambek, Markus
    5. Rieger, Jörg
    6. Bisdas, Sotirios
    7. Gstoettner, Wolfgang

    2007 - Forschungsinformationssystem des UKE
11. A phase II trial of docetaxel, cisplatin and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN).

    1. Baghi, Mehran
    2. Hambek, Markus
    3. Wagenblast, Jens
    4. May, Angelika
    5. Gstoettner, Wolfgang
    6. Knecht, Rainald

    2006 - Forschungsinformationssystem des UKE
12. Adjuvant docetaxel, cisplatin and 5-fluorouracil (TPF) in locally advanced squamous cell carcinoma of the head and neck.

    1. Baghi, Mehran
    2. Hambek, Markus
    3. May, Angelika
    4. Radeloff, Andreas
    5. Gstoettner, Wolfgang
    6. Knecht, Rainald

    2006 - Forschungsinformationssystem des UKE
13. AdOnco: a database for clinical and scientific documentation of head and neck oncology.

    1. Hambek, Markus
    2. Adunka, Oliver
    3. Baghi, Mehran
    4. Gstoettner, Wolfgang
    5. Knecht, Rainald

    2006 - Forschungsinformationssystem des UKE
14. Prestimulation of head and neck cancer cells with growth factors enhances treatment efficacy.

    1. Hambek, Markus
    2. Werner, Christian
    3. Baghi, Mehran
    4. Gstöttner, Wolfgang
    5. Knecht, Rainald

    2006 - Forschungsinformationssystem des UKE
15. Reduction of cisplatin dosage by ZD 1839.

    1. Hambek, Markus
    2. Baghi, Mehran
    3. Strebhardt, Klaus
    4. Strebhard, Klaus
    5. Baumann, Helena
    6. Gstöttner, Wolfgang
    7. Knecht, Rainald

    2005 - Forschungsinformationssystem des UKE
16. EGFR-antibody-supplemented TPF chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment.

    1. Knecht, Rainald
    2. Peters, Silke
    3. Hambek, Markus
    4. Solbach, Christine
    5. Baghi, Mehran
    6. Gstöttner, Wolfgang

    2005 - Forschungsinformationssystem des UKE
17. The efficacy of MRI with ultrasmall superparamagnetic iron oxide particles (USPIO) in head and neck cancers.

    1. Baghi, Mehran
    2. Mack, Martin G
    3. Hambek, Markus
    4. Rieger, Joerg
    5. Vogl, Thomas
    6. Gstoettner, Wolfgang
    7. Knecht, Rainald

    2005 - Forschungsinformationssystem des UKE
18. Iressa (ZD 1839) inhibits phosphorylation of three different downstream signal transducers in head and neck cancer (SCCHN).

    1. Hambek, Markus
    2. Baghi, Mehran
    3. Baumaun, Helena
    4. Strebhardt, Klaus
    5. Strebhard, Klaus
    6. Adunka, Oliver
    7. Gstöttner, Wolfgang

    2005 - Forschungsinformationssystem des UKE
19. Patient-based cross-platform comparison of oligonucleotide microarray expression profiles.

    1. Schlingemann, Joerg
    2. Habtemichael, Negusse
    3. Ittrich, Carina
    4. Toedt, Grischa
    5. Kramer, Heidi
    6. Hambek, Markus
    7. Knecht, Rainald

    2005 - Forschungsinformationssystem des UKE
20. STAT 3 activation in head and neck squamous cell carcinomas is controlled by the EGFR.

    1. Hambek, Markus
    2. Baghi, Mehran
    3. Strebhardt, Klaus
    4. Strebhard, Klaus
    5. May, Angelika
    6. Adunka, Oliver
    7. Gstöttner, Wolfgang

    2004 - Forschungsinformationssystem des UKE